84 results
8-K
ACUR
Acura Pharmaceuticals, Inc
25 Sep 23
Departure of Directors or Certain Officers
4:10pm
generic pharmaceutical manufacturer to an innovative specialty pharmaceutical company.
Remarking on the Mr. Wesson's retirement, Robert Jones, CEO stated … the Board to continue to avail itself of his wisdom, judgment and experience."
The vacancy on our Board created by Mr. Wesson's retirement will remain
8-K
EX-99.1
ACUR
Acura Pharmaceuticals, Inc
9 Oct 18
Entry into a Material Definitive Agreement
4:30pm
for a payment of $1.5 million. Mr. Schutte’s loans to the Company total $4.0 million. Pursuant to the terms of Mr. Schutte’s debt, after the retirement
8-K
EX-3.2
poyb09w90f f6
14 May 18
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
EX-1.1
fthsh4zv6tswre4 u1iu
18 Apr 13
Entry into a Material Definitive Agreement
12:00am
8-K
q57xcbulo
27 Jul 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
k0oatb6ebbnclbk6
11 Jul 11
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
7w7q0lx
11 Jul 11
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
EX-3.1
33fxje8ixcj9f
3 Mar 09
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
EX-10.2
3m0uf9s36 ykj8n0vk
10 Jul 08
Departure of Directors or Principal Officers
12:00am
8-K
EX-10.3
mzmqg
10 Jul 08
Departure of Directors or Principal Officers
12:00am